CD274 and non-small cell lung carcinoma: Clinical studies have shown some promising antitumor activity of sotorasib or adagrasib in patients with KRAS-G12C-mutated NSCLC that previously had been treated with platinum-based chemotherapy and/or PD-1/PD-L1 blockade.